OmnImmune (TC BioPharm)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameOmnImmune (TC BioPharm)
Drug Alias NameEx-vivo expanded allogeneic γδ T-lymphocytes(TC BioPharm)Gamma-Delta (γδ)T Cell Therapy TCB-002γδT Cell Therapy TCB-002TCB-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTc Biopharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCytoMed Therapeutics LtdTc Biopharm Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A